AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR HODGKINS-DISEASE - A 5-YEAR SINGLE-CENTER EXPERIENCE

被引：5

作者：

AGER, S ^{[1
]}

WIMPERIS, JZ ^{[1
]}

TOLLIDAY, B ^{[1
]}

JESTICE, K ^{[1
]}

BASS, G ^{[1
]}

BAGLIN, T ^{[1
]}

MARCUS, RE ^{[1
]}

机构：

[1] ADDENBROOKES HOSP,DEPT HAEMATOL,BONE MARROW TRANSPLANT UNIT,CAMBRIDGE CB2 2QQ,ENGLAND

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 13卷 / 3-4期

关键词：

ABMT; HODGKINS DISEASE; RELAPSED; REFRACTORY;

D O I：

10.3109/10428199409056290

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The results from 40 patients who have undergone autologous bone marrow transplantation (ABMT) for relapsed or refractory Hodgkin's disease between March 1988 and September 1992 have been analysed. In contrast to our results in patients with relapsed HD, our results in patients with refractory HD are comparatively poor. Conventional salvage chemotherapy also seems inappropriate in these patients and we therefore believe they should be offered high-dose chemotherapy before their disease becomes refractory to conventionally scheduled regimens. Peripheral blood stem cell (PBSC) transplant now offers an attractive alternative to ABMT and may replace both intensive salvage chemotherapy and ABMT as the optimum treatment for patients who fail to respond to conventional chemotherapy regimens.

引用

页码：263 / 272

页数：10

共 39 条

[1] Canellos G.P., Anderson J.R., Propert K.J., Chemotherapy of advanced Hodgkin's Disease with MOPP, ABVD, or MOPP alternating with ABVD, N. Engl. J. Med., 327, pp. 1478-1484, (1992)
[2] DeVita V.T., Simon R.M., Wesley M., Curability of advanced Hodgkin's Disease with chemotherapy, Ann. Int. Med., 92, pp. 587-595, (1980)
[3] Frei E., Luce J.K., Gamble J.F., Combination chemotherapy in advanced Hodgkin's Disease: Induction and maintenance of remission, Ann. Intern. Med., 79, pp. 376-382, (1973)
[4] Longo D.L., Young R.C., Wesley M., Twenty years of MOPP therapy for Hodgkin's Disease, J. Clin. Oncol., 4, pp. 1295-1306, (1986)
[5] Bonadonna G., Santoro A., Gianni A.M., Primary and salvage Chemotherapy in Advanced Hodgkin's Disease: The Milan Cancer Institute Experience, Ann. Oncol., 2, Suppl. 1, pp. 9-16, (1991)
[6] Bonadonna G., Santoro A., Current Issues in the Management of Advanced Hodgkin's Disease, Blood Rev., 4, pp. 69-73, (1990)
[7] Hagemeister F.B., Tannir N., McLaughlin P., MIME Chemotherapy as Treatment for Recurrent Hodgkin's Disease, J. Clin. Oncol., 5, Suppl. 4, pp. 556-561, (1987)
[8] Bonadonna G., Viviani S., Valagussa P., Third-line salvage Chemotherapy in Hodgkin's Disease, Semin. Oncol., 12, Suppl. 2, pp. 23-25, (1985)
[9] Hancock B.W., Vaughan G., Hudson V., Hudson B., LOPP Alternating with EVAP is superior to LOPP Alone in the Initial Treatment of Advanced Hodgkin's Disease
[10] Results of a British National Lymphoma Investigation Trial, J. Clin. Oncol., 10, Suppl. 8, pp. 1252-1258, (1992)

← 1 2 3 4 →